Le Lézard
Classified in: Health, Science and technology
Subject: PDT

PayerAlly Achieves HITRUST e1 Certification Demonstrating Foundational Cybersecurity


HITRUST e1 Certification validates PayerAlly is committed to foundational cybersecurity controls and information risk management protecting healthcare information for their clients.

ORLANDO, Fla., Oct. 14, 2024 /PRNewswire/ -- PayerAlly, a leading provider of strategic consulting in pharmacy benefits, today announced its healthcare claims (pharmacy and medical) data management infrastructure has earned certified status by HITRUST for foundational cybersecurity.

HITRUST e1 Certification demonstrates that the organization's healthcare data management infrastructure is focused on the most critical controls to demonstrate that essential cybersecurity hygiene is in place. The e1 assessment is one of three progressive HITRUST assessments that leverage the HITRUST Framework (HITRUST CSF) to prescribe cyber threat adaptive controls that are appropriate for each assurance type.

"In today's environment of healthcare breaches, it's imperative that organizations, including benefit consultants like ours keep pace with current and emerging threats," said Bill Guerci, Chief Operating Officer and Information Security Coordinator at PayerAlly. "We are pleased to demonstrate to our current and future clients our commitment to cybersecurity and data protection through HITRUST e1 Certification."

"The HITRUST e1 Validated Assessment is a good tool for cyber-aware organizations like PayerAlly that want to build assurances and progressively demonstrate due diligence around information security and privacy," said Robert Booker, Chief Strategy Officer at HITRUST. "We applaud PayerAlly for their commitment to cybersecurity and successful completion of their HITRUST e1 Certification."

About PayerAlly
Pharmacy Benefit Consulting without Conflicts

PayerAlly media contact:
Will McHugh, President
800-515-2162
[email protected] 

SOURCE PayerAlly LLC


These press releases may also interest you

at 00:07
The pilot aims to speed up the process for safely and securely finding participants for UK clinical trials, improving efficiencies and opportunities for people to take part in research and access innovative new medicines. The pilot will test a new...

4 nov 2024
BioCity Biopharma (BioCity) announced late-breaking results of the 2-SUCCEED clinical trial of SC0062, a selective endothelin receptor type A (ETA) antagonist, for the treatment of IgA Nephropathy (IgAN). These results were presented at the Oral...

4 nov 2024
Kenvue Canada Inc., a division of Kenvue Inc. ("Kenvue"), the world's largest pure-play consumer health company by revenue and maker of iconic brands such as Tylenol®, Aveeno, Listerine® and Neutrogena®, announced the completion of its newly...

4 nov 2024
Hugel Inc., a leading global medical aesthetics company, said on Tuesday that WELLAGE, its clinical derma cosmetics brand for skin wellness, joined the festival K-beauty Boost in NYC 2024 at the Korean Cultural Center New...

4 nov 2024
Acoustiic Inc. has received a research funding agreement from the Focused Ultrasound Foundation (FUS) to adapt their WaveMatrixtm platform to explore the therapeutic applications of ultrasound in companion animals. Acoustiic's platform provides an...

4 nov 2024
ScriptsMD is an innovative healthcare solution that provides Americans with affordable access to semaglutide weight loss treatment while addressing nationwide medication shortages. The company's comprehensive program delivers semaglutide at just $239...



News published on and distributed by: